Genetic Variations Associated with Atopic Dermatitis Differ Among Races


A new cohort shows FLG loss-of-function variations are often different among AD pediatric patients with different ancestries.

David J. Margolis, MD, PhD

David J. Margolis, MD, PhD

A new study shows significant variation in filaggrin gene (FLG) function among pediatric patients belonging to different races with atopic dermatitis (AD).

The findings, from a cohort assessing association between patient characteristics and their state of function variants with FLG, further evidences the role of heritability in AD prevalence and severity, but a discord in genetic variation interpretation.

An investigative team led by David J. Margolis, MD, PhD, of the Perelman School of Medicine at the University of Pennsylvania, conducted a US-based cohort analysis of children with mild to moderate AD identified through the Pediatric Eczema Elective Registry (PEER).

With an estimated heritability of up to 84% of all patients, AD’s most frequently reported genetic variants associated with skin barrier dysfunction is exon 3 loss-of-function (LoF) variants in FLG—aa gene which codes for skin barrier protein that is associated with AD in the event of LoF.

Margolis and colleagues noted that AD patients of African ancestry do not frequently exhibit FLG LoF variants—a trend that breaks from that of patients from Asian or European ancestry.

“Several studies have shown that the prevalence of FLG LoF variants differs by race,” investigators wrote. “The goals of the present study are to comprehensively describe and compare results from fine sequencing of FLG LoF variants in US children of African and European ancestry and to evaluate the association of these variants with the risk of onset and the persistence of AD.”

Investigators included 741 children from the PEER registry for their analysis, with an enrollment period that spanned June 2005 through July 2017. Mean patient age was 1.97 years, with a majority (n= 394 [53.2%]) female and white (n= 394 [53.2%]). Another 44% (n= 326) were African American.

Massively parallel sequencing (MPS) technology helped investigators finds 23 FLG LoF variants among children with AD. Variants were present in 177 total participants (23.9%) in the full cohort—124 (31.5%) being white and 50 (15.3%) being African American.

A white child carrying any FLG LoF variant compared to an African American child with AD carried an odds ratio of 2.44 (95% CI: 1.76 — 3.39). Some variants were noted to not be observed at all in white patients, investigators wrote.

Margolis and colleagues noted that, as genetic testing is more embraced by the healthcare community to help distinguish individual illness risk and severity, their new findings show the risk of broadly analyzing findings for a common condition such as AD. In fact, not many studies on the association between FLG LoF variants and AD risk even address the patient’s eventual experience with the disease.

“In fact, for many patients, by the time genetic testing is complete, the child already has clinical manifestations of the disease, and parents or patients want to know not only if their child is at increased risk of developing the disease but also information about disease course,” they wrote.

That said, they backed their conclusion that FLG LoF variant is twice more frequent in white children with AD than African American children, despite the latter patient population reporting more prevalent and persistent forms of the disease. Following the standard practice of LFG LoF variant testing would result in about 64% of African American children and 8% of white children being improperly classified.

“Any planned genetic diagnostic test for AD based on FLG LoF variants must be inclusive and not rely on the most frequently studied variants,” they concluded. “Furthermore, use of testing needs to carefully differentiate between disease diagnosis and disease prognostication.”

The study, “Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis,” was published online in JAMA Dermatology.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
© 2024 MJH Life Sciences

All rights reserved.